XSpray Pharma AB (XSPRAY) — Cash Flow-to-Debt Ratio
XSpray Pharma AB (XSPRAY) has a Cash Flow-to-Debt Ratio of -0.21x as of June 2026, meaning its operating cash flow of Skr-36.95 Million could theoretically repay 0% of its total liabilities (Skr173.68 Million) in one year. See XSpray Pharma AB financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
XSpray Pharma AB Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for XSpray Pharma AB across 11 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of XSpray Pharma AB.
Annual Cash Flow-to-Debt Ratio for XSpray Pharma AB (2015–2025)
Year-by-year debt coverage analysis for XSpray Pharma AB. Check XSPRAY cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.17x | Skr-193.16 Million | Skr164.70 Million | ▲ +8.6% |
| 2024 | -1.28x | Skr-222.37 Million | Skr173.25 Million | ▲ +54.6% |
| 2023 | -2.83x | Skr-203.28 Million | Skr71.85 Million | ▲ +24.5% |
| 2022 | -3.75x | Skr-110.18 Million | Skr29.41 Million | ▼ -126.1% |
| 2021 | -1.66x | Skr-51.61 Million | Skr31.15 Million | ▲ +21.3% |
| 2020 | -2.10x | Skr-47.79 Million | Skr22.72 Million | ▼ -65.7% |
| 2019 | -1.27x | Skr-34.24 Million | Skr26.96 Million | ▲ +22.9% |
| 2018 | -1.65x | Skr-17.75 Million | Skr10.77 Million | ▲ +14.1% |
| 2017 | -1.92x | Skr-11.04 Million | Skr5.75 Million | ▼ -492.8% |
| 2016 | -0.32x | Skr-1.74 Million | Skr5.39 Million | ▲ +93.3% |
| 2015 | -4.82x | Skr-12.96 Million | Skr2.69 Million | — |